Top Markets
#1 Akedo Akedo +59.31%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +50.07%
#4 Velvet Velvet +43.76%
#5 Black Phoenix Black Phoenix +34.55%
#6 τemplar τemplar +26.67%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +18.66%
#8 Bitway Bitway +18.26%
#9 Perle Perle +16.48%
#10 Cap Cap +16.47%
Coin of the day
Akedo Akedo
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
CohBar, Inc. CohBar, Inc.

CohBar, Inc.

CWBR
Pozycja w akcjach #38304
CohBar Inc. is a clinical-stage biotechnology company dedicated to the... CohBar Inc. is a clinical-stage biotechnology company dedicated to the discovery and advancement of therapies that leverage mitochondrial biology, known as mitochondria-based therapeutics (MBTs). Their primary objective is to combat chronic conditions and diseases associated with aging. These MBTs are being developed to address a broad spectrum of medical challenges, including non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis (IPF), type 2 diabetes, acute respiratory distress syndrome (ARDS), various cancers, and cardiovascular disorders like Alzheimer's disease. Their flagship clinical asset is CB4211, an innovative, optimized analogue of the MOTS-c mitochondrial-derived peptide. This candidate is currently undergoing Phase Ib evaluation as part of a larger Phase Ia/Ib clinical trial, specifically targeting non-alcoholic steatohepatitis (NASH) and obesity. Beyond their clinical work, CohBar's preclinical portfolio features CB5138 analogs aimed at fibrotic conditions, as well as CB5064 analogs being explored for their potential in treating ARDS linked to COVID-19. Established in 2007, CohBar, Inc. maintains its corporate headquarters in Menlo Park, California.
Cena akcji
$0.41
Ostatnia synchronizacja: 2025-01-23
Kapitalizacja rynkowa
$1.08M
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
US
Handel CohBar, Inc. (CWBR)

Kategoria

Healthcare
Przychody dla CohBar, Inc. (CWBR)
Przychody w Jun 2023 TTM: 0.00
Według najnowszych raportów finansowych CohBar, Inc., obecny przychód firmy (TTM) wynosi 0.00. W roku 2021 firma osiągnęła przychód w wysokości 0.00 równa się przychodu z roku 2020, który wynosił 0.00. Przychód to całkowita kwota dochodu generowana przez firmę ze sprzedaży towarów lub usług. W przeciwieństwie do zysku, nie są odliczane żadne koszty.
Historia przychodów firmy CohBar, Inc. od 2012 do 2026
Przychody na koniec każdego roku
Rok Przychody Zmień
2026 (TTM) 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
Przychody podobnych firm lub konkurentów
Firma Przychody Różnica w przychodach Kraj
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE